title: Primary central nervous system lymphomas in 72 immunocompetent patients: pathologic findings and clinical correlations. Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS)
abstract: We reviewed 72 primary central nervous system lymphomas occurring in immunocompetent patients. The cases were reviewed for clinical data, histology, immunophenotype, bcl-2 and p53 expression, and Epstein-Barr virus association. Follow-up was available for 40 patients included in the Groupe Ouest Est d'étude des Leucénies et Autres Maladies du Sang (GOELAMS) lymphomes cérébraux primitifs (LCP 88) trial. Each diagnosis, requiring a consensus among at least 3 pathologists, was performed according to the recent Revised European-American Lymphoma classification and equivalents in the updated Kiel classification. Tumors were predominantly classified as diffuse large B-cell lymphomas. There were 3 T-cell lymphomas and 1 Hodgkin lymphoma. The proteins bcl-2 and p53 were expressed in 35% and 16% of the tested cases, respectively. Epstein-Barr virus was not found by in situ hybridization except in the case classfied as a cerebral localization of Hodgkin disease. No significant association was found between subtypes, bcl-2 or p53 expression, and patient survival. From the standpoint of their biologic characteristics, primary central nervous system lymphomas are very similar to systemic diffuse large B-cell lymphomas. In contrast to AIDS-related primary central nervous system lymphomas, primary central nervous system lymphomas are rarely associated with Epstein-Barr virus and in immunocompetent patients they express bcl-2 at a relatively low rate.
authors.affiliation: Service de Neuropathologie, Groupe hospitalier Pitié-Salpêtrière, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Camilleri-Broët
authors.forename: A
authors.initials: A
authors.lastname: Martin
authors.forename: A
authors.initials: A
authors.lastname: Moreau
authors.forename: R
authors.initials: R
authors.lastname: Angonin
authors.forename: D
authors.initials: D
authors.lastname: Hénin
authors.forename: M F
authors.initials: MF
authors.lastname: Gontier
authors.forename: M C
authors.initials: MC
authors.lastname: Rousselet
authors.forename: S
authors.initials: S
authors.lastname: Caulet-Maugendre
authors.forename: P
authors.initials: P
authors.lastname: Cuillière
authors.forename: T
authors.initials: T
authors.lastname: Lefrancq
authors.forename: K
authors.initials: K
authors.lastname: Mokhtari
authors.forename: M
authors.initials: M
authors.lastname: Morcos
authors.forename: P
authors.initials: P
authors.lastname: Broët
authors.forename: M
authors.initials: M
authors.lastname: Kujas
authors.forename: J J
authors.initials: JJ
authors.lastname: Hauw
authors.forename: B
authors.initials: B
authors.lastname: Desablens
authors.forename: M
authors.initials: M
authors.lastname: Raphaël
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016543:Central Nervous System Neoplasms / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics; D006689:Hodgkin Disease / Q000276:immunology / Q000473:pathology; D006801:Humans; D007121:Immunocompetence; D007150:Immunohistochemistry; D016130:Immunophenotyping; D017403:In Situ Hybridization; D008223:Lymphoma / Q000276:immunology / Q000382:microbiology / Q000473:pathology*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000276:immunology / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D019253:Proto-Oncogene Proteins c-bcl-2; D012367:RNA, Viral; D016159:Tumor Suppressor Protein p53